Personalized CAR-T for children with high-risk B-ALL
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial studies a personalized type of immune therapy (CAR-T) made from your own cells to treat pediatric B-ALL that has returned or not responded to prior treatment. It aims to see how well this manufactured CAR-T works and how safely it can be given.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) have B-ALL or another listed B-cell leukemia that shows CD19 on tests
- Your disease fits a specific situation (like relapse, not responding, or early return after similar cell therapy)
- You are between 0 and 29 years old
- Your organs and breathing/heart are strong enough based on blood tests and heart/lung checks
- You can’t have certain infections or illnesses (including HIV, active hepatitis B/C, uncontrolled infection)
- You can’t be pregnant or breastfeeding, and you/your family must use birth control if able to have a pregnancy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two different engineered immune cell therapies to treat B-ALL (a leukemia). It’s designed for young people whose disease has come back, is hard to treat, or didn’t respond well to similar cell therapies.
This trial tests a personalized immune-cell therapy (CAR T cells) made to attack B-cell cancers that have come back or did not respond to prior treatment. It aims to see how well the treatment works and how safe it is in children and young adults.
This trial tests a CAR T-cell therapy that targets CD19 on cancer cells. It is for children whose B-cell acute lymphoblastic leukemia or aggressive B-cell non-Hodgkin lymphoma has come back or not responded to other treatments.
This trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) found on leukemia cells. It is for children and young adults whose B-ALL has come back multiple times, or who have not responded to other treatments.
This trial uses a one-time infusion of specially grown immune cells (CAR T cells) from a healthy donor to attack leukemia that has come back or not responded to prior treatments. It is for children and young adults with B-cell acute lymphoblastic leukemia that still shows the CD19 marker.
This Phase 1/2 study tests a type of immune therapy (CAR-T cells) made to recognize CD19 and CD22, two markers on B-ALL cells. It is for children and adults with B-ALL that has come back or did not respond to standard treatments, aiming to improve outcomes when other options have failed.
Hear when a new B Cell Acute Lymphoblastic Leukemia (B-ALL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.